证券代码：300111 证券简称：向日葵 公告编号：2025—019 浙江向日葵大健康科技股份有限公司 关于召开2024年年度股东大会的提示性公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整， 没有虚假记载、误导性陈述或重大遗漏。 浙江向日葵大健康科技股份有限公司（以下简称"公司"）第六届董事会第 五次会议审议通过了《关于召开 2024 年年度股东大会的议案》，定于 2025 年 5 月 9 日召开公司 2024 年年度股东大会。本次股东大会会议通知已于 2025 年 4 月 18 日在巨潮资讯网（http://www.cninfo.com.cn）上发布。现将会议有关事宜提示 如下： 一、召开会议的基本情况 1、股东大会届次：2024年年度股东大会 2、股东大会的召集人：本次股东大会由董事会召集，经公司第六届董事会 第五次会议决议通过。 3、会议召开的合法、合规性：本次股东大会的召开符合有关法律、行政法 规、部门规章、规范性文件和公司章程的相关规定。 4、现场会议召开时间：2025年5月9日（星期五）14:30 网络投票时间：通过深圳证券交易所交易系统进行投票的具体时间为：2025 年5月9日9 ...

Core Insights - The company reported a total revenue of 72.23 million yuan for Q1 2025, a decrease of 11.46 million yuan compared to the same period last year, representing a year-on-year decline of 13.69% [1] - The net profit attributable to shareholders was -0.13 million yuan, a decrease of 0.68 million yuan year-on-year, reflecting a significant decline of 123.77% [1] - The latest gross profit margin is 17.94%, down 4.65 percentage points from the previous quarter and down 3.69 percentage points year-on-year [2] Financial Performance - Operating cash flow was 28.30 million yuan [1] - The latest return on equity (ROE) is -0.02%, a decrease of 0.10 percentage points year-on-year [2] - The diluted earnings per share is -0.00 yuan, which is essentially flat compared to the same period last year but shows a decline of 125.00% year-on-year [2] Efficiency Metrics - The total asset turnover ratio is 0.07 times, unchanged from the previous year [2] - The inventory turnover ratio is 0.42 times, a decrease of 0.15 times year-on-year, representing a decline of 26.22% [2] Shareholder Information - The number of shareholders is 65,200, with the top ten shareholders holding 433 million shares, accounting for 33.64% of the total share capital [2] - The largest shareholder is Wu Jianlong, holding 28.7 million shares [2] Leverage - The latest debt-to-asset ratio is 16.68% [3]

Financial Performance - The company's revenue for Q1 2025 was ¥72,231,172.35, a decrease of 13.69% compared to ¥83,692,914.60 in the same period last year[2]. - The net profit attributable to shareholders was -¥130,948.16, representing a decline of 123.77% from ¥551,007.76 year-on-year[2]. - The company's basic and diluted earnings per share were both -¥0.0001, a decrease of 125.00% from ¥0.0004 in the same period last year[2]. - Net profit for the period was ¥167,587.19, down from ¥1,372,734.93, indicating a significant decline in profitability[22]. - The total comprehensive income attributable to the parent company was -127,682.16, compared to 592,027.76 in the previous period[23]. Cash Flow - The net cash flow from operating activities increased significantly by 308.41% to ¥28,296,923.31, compared to ¥6,928,601.93 in the previous year[2]. - Operating cash inflow for Q1 2025 reached ¥101.22 million, a 44.80% increase compared to ¥69.90 million in Q1 2024, primarily due to increased cash receipts from sales[12]. - Operating cash outflow for Q1 2025 was ¥72.92 million, up 15.79% from ¥62.97 million in Q1 2024, mainly due to higher cash payments for raw materials[12]. - Cash inflows from operating activities totaled 101,217,105.86, compared to 69,903,578.08 in the previous period, indicating a growth of approximately 45%[24]. - The cash outflows from operating activities amounted to 72,920,182.55, compared to 62,974,976.15 in the previous period, reflecting an increase of about 15%[24]. - The net cash flow from investing activities was -45,372,259.11, worsening from -530,279.24 in the previous period[24]. - The net cash flow from financing activities was -2,034,883.79, compared to -225,752,723.83 in the previous period, showing a significant reduction in cash outflow[24]. Assets and Liabilities - The total assets at the end of Q1 2025 were ¥987,891,994.10, down 1.12% from ¥999,118,426.12 at the end of the previous year[2]. - Total liabilities decreased to ¥164,739,264.83 from ¥176,136,550.04, reflecting a reduction of about 6.5%[18]. - The company's cash and cash equivalents showed a decrease in current assets, with total current assets at ¥775,050,956.39 compared to ¥787,898,263.37, a decline of approximately 1.6%[19]. - The total equity attributable to shareholders decreased to ¥686,117,314.46 from ¥686,244,996.62, a slight decline of about 0.02%[19]. Development and Expenditures - The company reported a significant increase in development expenditures, rising by 38.14% to ¥16,288,668.59, attributed to new capitalized R&D projects[6]. - Research and development expenses were ¥4,442,561.10, down from ¥5,674,800.96, a decrease of about 21.7% year-over-year[21]. - The company reported a significant increase in development expenditures to ¥16,288,668.59 from ¥11,791,242.79, an increase of approximately 38.5%[19]. Shareholder Information - The total number of ordinary shareholders at the end of the reporting period was not specified, but the largest shareholder, Wu Jianlong, holds 28.79% of shares, totaling 370,630,131 shares[14]. - Wu Jianlong's shares include 245 million pledged shares, indicating a significant portion of his holdings is under collateral[14]. Other Financial Metrics - The company recorded a 100% increase in trading financial assets, amounting to ¥40,054,465.76, due to the addition of short-term trading financial products[6]. - The company’s weighted average return on equity was -0.02%, down from 0.12% year-on-year[2]. - The company’s contract liabilities increased by 76.32% to ¥1,889,987.89, reflecting an increase in advance payments received[6]. - The company reported no investment income from asset disposals in Q1 2025, contrasting with the previous year where such income was recorded[12]. - The impact of exchange rate fluctuations on cash and cash equivalents was a gain of ¥736,528.96, a 93.87% increase from ¥379,906.82 in Q1 2024[12]. - The company has not engaged in any short-term borrowing activities in Q1 2025, contrasting with the previous year where such activities generated cash inflow of ¥8.06 million[12].

浙江向日葵大健康科技股份有限公司 2024 年度董事会工作报告 （一）董事会会议召开情况 报告期内，公司董事会根据《公司法》和《公司章程》赋予的职责，严格执 行股东大会各项决议，积极推进董事会各项决议实施，及时研究和决策公司重大 事项，确保董事会运作规范、务实、高效。 2024 年召开 9 次董事会会议，审议通过了 34 项议案。董事会会议的召集、 召开程序，符合《公司法》《证券法》等法律、法规、规范性文件及《公司章程》 的规定。 2024 年董事会召开情况如下： 1、2024 年 2 月 2 日召开公司第五届董事会第二十五次会议，审议通过了以 下议案： 2024 年，浙江向日葵大健康科技股份有限公司（以下简称"公司"）董事会 严格按照《公司法》《证券法》《深圳证券交易所上市公司自律监管指引第 2 号— —创业板上市公司规范运作》等法律法规以及《公司章程》《公司董事会议事规 则》等规章制度的规定，本着对公司及全体股东负责的态度，积极有效地行使董 事会职权，认真贯彻落实股东大会的各项决议，勤勉尽责地开展董事会各项工作。 现将 2024 年度董事会主要工作情况报告如下： 一、2024 年度经营情况 2024 年， ...

证券代码：300111 证券简称：向日葵 公告编号：2025—007 浙江向日葵大健康科技股份有限公司 关于公司2025年续聘会计师事务所的公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整， 没有虚假记载、误导性陈述或重大遗漏。 浙江向日葵大健康科技股份有限公司（以下简称"公司"）于2025年4月17 日召开了第六届董事会第五次会议、第六届监事会第三次会议，审议通过了《关 于公司2025年续聘会计师事务所的议案》，拟续聘立信会计师事务所（特殊普通 合伙）（以下简称"立信"）为公司2025年度审计机构。本议案尚需提交公司股 东大会审议通过，现将相关事宜公告如下： 一、 拟续聘会计师事务所事项的情况说明 立信是一家主要为上市公司提供审计服务的会计师事务所，具有证券期货业 务从业资格，具备多年为上市公司提供优质审计服务的丰富经验和专业能力，已 连续多年为公司提供审计服务，在以往年度对公司的审计过程中尽职尽责，能够 按照中国注册会计师审计准则要求，客观、公正的对公司会计报表发表意见。为 保证审计工作的连续性，公司拟继续聘请立信为公司 2025 年度审计机构。公司 董事会提请公司股东大会授权公司管理层根据 ...

证券代码：300111 证券简称：向日葵 公告编号：2025—011 浙江向日葵大健康科技股份有限公司 （二）2024 年度募集资金使用及余额 | 募集资金明细 | 金额（元） | | --- | --- | | 2023 年 12 月 31 日募集资金净额 | 118,775,601.17 | | 减：募集资金使用金额 | 115,886,867.49 | | 加：募集资金专户利息收入减去支付银行手续费 | 998,930.92 | | 减：募集资金账户注销结转 | 3,887,664.60 | | 2024 年 12 月 31 日募集资金专户余额 | 0.00 | 截至 2024 年 12 月 31 日，公司募集资金实际使用情况为： 注：公司于 2024 年 8 月 23 日发布关于注销募集资金专用账户的公告，公告中对募 集资金专户注销情况说明如下："鉴于公司募集资金投资项目之"补充流动资金" 的募集资金已按照相关规定使用完毕，上述募集资金专户将不再使用，为减少管理 成本，公司决定对上述募集资金专户予以注销，并将上述募集资金专户中节余募集 资金利息收入人民币 3,887,664.60 元转入公司基本账户。 ...